Abstract
Objective To analyze the clinical efficacy and outcomes of adult patients who underwent ABO-incompatible living donor liver transplantation. Methods The clinical data of 7 patients who underwent ABO-incompatible living donor liver transplantation at the Henan Provincial People's Hospital and Zhengzhou People's Hospital from January 2013 to December 2015 were analyzed retrospectively. Age, gender, primary disease, blood type antibody level, graft volume/standard liver volume (GV/SLV), postoperative complications and prognosis were analyzed. Results The recipients' average GV/SLV was 52.0%. There were 4 recipients who underwent splenectomy, including 3 patients who underwent the procedure concurrently, and one patient who underwent the procedure a few years before, the liver transplantation. Seven recipients were treated with plasmapheresis, Rituximab and Basiliximab. No patients experienced acute rejection during the perioperative period, and the 1-year survival rate was 85.7% (6/7). Conclusion ABO-incompatible liver transplantation in adult living donor can have favorable clinical outcomes using appropriate preoperative evaluation for recipients, optimized surgical procedures, pretransplant plasmapheresis, and perioperative Rituximab, Basiliximab injection and intravenous immunoglobulin administration. Key words: Living donor liver transplantation; ABO-incompatible; Plasmapheresis; Prognosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
